SIGA Technologies, Inc.

NasdaqGM SIGA

SIGA Technologies, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: 49.06%

SIGA Technologies, Inc. Return on Equity (ROE) is 49.06% for the Trailing 12 Months (TTM) ending September 30, 2024, a 1,524.22% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

SIGA Technologies, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -3.44%, a -105.23% change year over year.
SIGA Technologies, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was 65.91%, a 377.87% change year over year.
SIGA Technologies, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was 13.79%, a -57.22% change year over year.
SIGA Technologies, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2020 was 32.24%, a -32.58% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGM: SIGA

SIGA Technologies, Inc.

CEO	Dr. Diem Nguyen M.B.A., Ph.D.
IPO Date	Sept. 10, 1997
Location	United States
Headquarters	31 East 62nd Street
Employees	45
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Vaccines

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Key trends

Past 5 years